Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.

@article{Riddle2001FluvoxamineFC,
  title={Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.},
  author={Mark A. Riddle and Elizabeth A. Reeve and Jose A. Yaryura-Tobias and H M Yang and James L. Claghorn and Gary R. Gaffney and John H. Greist and D E Holland and Brian J. Mcconville and Teresa A Pigott and John T. Walkup},
  journal={Journal of the American Academy of Child and Adolescent Psychiatry},
  year={2001},
  volume={40 2},
  pages={
          222-9
        }
}
  • M. Riddle, E. Reeve, +8 authors J. Walkup
  • Published 1 February 2001
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
OBJECTIVE To determine the safety and efficacy of fluvoxamine for the treatment of children and adolescents with obsessive-compulsive disorder (OCD) with a double-blind, placebo-controlled, multicenter study. METHOD Subjects, aged 8 to 17 years, meeting DSM-III-R criteria for OCD were recruited from July 1991 to August 1994. After a 7- to 14-day single-blind, placebo washout/screening period, subjects were randomly assigned to fluvoxamine 50 to 200 mg/day or placebo for 10 weeks. Subjects who… 
View on PubMed
doi.org
316 Citations
Highly Influential Citations
9
Background Citations
66
Methods Citations
13
Results Citations
9

316 Citations

Citation Type

Citation Type

Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
TLDR
Paroxetine is an effective and generally well-tolerated treatment for obsessive-compulsive disorder in children and adolescents.
Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
TLDR
Fluoxetine was well tolerated and effective for the treatment of child and adolescent OCD, but fluoxettine's full effect took more than 8 weeks to develop.
Citalopram treatment of children and adolescents with obsessive–compulsive disorder: A preliminary report
TLDR
The primary data suggest the efficacy and tolerability of citalopram in young patients with OCD in an 8‐week, open‐label study.
The pediatric obsessive-compulsive disorder treatment study: rationale, design, and methods.
TLDR
The Pediatric OCD Treatment Study is a multicenter, randomized, masked clinical trial designed to evaluate the relative benefit and durability of four treatments for children and adolescents with OCD: sERTraline, CBT, combination of sertraline andCBT, and pill placebo.
12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive–Compulsive Disorder
TLDR
The study failed to demonstrate superiority of riluzole over placebo as an adjunctive treatment for children with childhood-onset OCD, but future studies may show benefits for less treatment-refractory children with fewer concomitant medications.
Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder.
TLDR
Sertraline is effective in the treatment of childhood and adolescent OCD, with initial acute response converting to remission and improved functional status in a substantial proportion of patients.
Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial.
Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder.
TLDR
The treatment with GCBT may be effective in decreasing obsessive-compulsive symptoms in childhood obsessive-Compulsive disorder and should be considered as an alternative to either individual cognitive-behavioral therapy or a medication, such as sertraline.
A naturalistic study of referred children and adolescents with obsessive-compulsive disorder.
TLDR
Long-term naturalistic prospective studies in pediatric patients with OCD might represent an important source of information for everyday care regarding the effectiveness of a treatment over extended periods of time under routine clinical conditions.
Fluoxetine in acute treatment of children and adolescents with obsessive–compulsive disorder: a systematic review and meta-analysis
TLDR
Fluoxetine is associated with a significantly greater reduction in OCD severity, as measured by the CY-BOCS, NIMH-OC and CGI-S, in children and adolescents, and it is well tolerated inChildren and adolescents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
TLDR
The results suggest that fluoxetine is a generally safe and effective short-term treatment for children with OCD.
Treatment of obsessive—compulsive disorder with fluvoxamine: a multicentre, double‐blind, placebo‐controlled trial
TLDR
Fluvoxamine was significantly more effective than placebo as assessed by the Yale Brown Obsessive-Compulsive Scale (Y-BOCS), the National Institute of Mental Health Obsessives Compulsive (NIMH-OC) scale and (be Global Improvement item of the Clinical Global Impression (CGI) scale).
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
TLDR
Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.
Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.
TLDR
There was a significant improvement in observed and self-reported obsessions and compulsions that was independent of the presence of depressive symptoms at baseline and the treatment seems to be independent of an antidepressant effect.
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
TLDR
A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder, lending partial support to the serotonin hypothesis of OCD.
Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
TLDR
In a 1-year open label treatment, CMI continued to be effective and well tolerated and side effects were typical of tricyclic antidepressants.
Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
TLDR
Preliminary evidence suggests that short-term treatment of adolescents with fluvoxamine is relatively safe and may be effective for OCD and some affective spectrum symptoms.
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
TLDR
Fluoxetine was associated with a statistically significant reduction in OCD severity, including time engaged in obsessional and/or compulsive behaviors, and greater efficacy at 60 mg/d was observed.
Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison.
TLDR
The specificity of the antiobsessional effect of clomipramine and the need for maintenance treatment is documented, and age at onset, duration and severity of illness, type of symptom, and plasma drug concentrations did not predict clinical response.
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
TLDR
Results support the safety and efficacy of daily dosages of 50, 100, and 200 mg of sertraline in the short-term treatment of patients with OCD.
...
1
2
3
...